These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21098347)

  • 1. Metformin use and mortality among patients with diabetes and atherothrombosis.
    Roussel R; Travert F; Pasquet B; Wilson PW; Smith SC; Goto S; Ravaud P; Marre M; Porath A; Bhatt DL; Steg PG;
    Arch Intern Med; 2010 Nov; 170(21):1892-9. PubMed ID: 21098347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: the case of metformin.
    Eurich DT; Majumdar SR; McAlister FA; Tsuyuki RT; Johnson JA
    Arch Intern Med; 2011 Jun; 171(11):1042-3; author reply 1043. PubMed ID: 21670379
    [No Abstract]   [Full Text] [Related]  

  • 3. Metformin and heart failure: never say never again.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2012 Jan; 13(1):1-8. PubMed ID: 22149365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle brachial index as a prognostic marker of cardiovascular disease.
    Bundó M; Muñoz L; Pérez C; Montero JJ; Montellà N; Torán P; Pera G
    Ann Vasc Surg; 2010 Nov; 24(8):985-93. PubMed ID: 21035692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes mellitus and heart failure.
    Choy CK; Rodgers JE; Nappi JM; Haines ST
    Pharmacotherapy; 2008 Feb; 28(2):170-92. PubMed ID: 18225964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
    Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
    J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Bell DS
    Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
    [No Abstract]   [Full Text] [Related]  

  • 9. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin in heart failure.
    Inzucchi SE; Masoudi FA; McGuire DK
    Diabetes Care; 2007 Dec; 30(12):e129. PubMed ID: 18042738
    [No Abstract]   [Full Text] [Related]  

  • 11. Metformin use in decompensated heart failure.
    Boyd A; Nawarskas J
    Cardiol Rev; 2008; 16(5):269-72. PubMed ID: 18708828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
    McAlister FA; Eurich DT; Majumdar SR; Johnson JA
    Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease.
    van Kuijk JP; Flu WJ; Welten GM; Hoeks SE; Chonchol M; Vidakovic R; Verhagen HJ; Bax JJ; Poldermans D
    Eur Heart J; 2010 Apr; 31(8):992-9. PubMed ID: 20037181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for type 2 diabetes and coronary artery disease.
    DeVries JH
    N Engl J Med; 2009 Oct; 361(14):1408-9; author reply 1409-10. PubMed ID: 19802918
    [No Abstract]   [Full Text] [Related]  

  • 16. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
    Gulliford M; Latinovic R
    Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin therapy in patients with type 2 diabetes complicated by heart failure.
    Inzucchi SE; Masoudi FA; McGuire DK
    Am Heart J; 2007 Dec; 154(6):e45. PubMed ID: 18035066
    [No Abstract]   [Full Text] [Related]  

  • 18. Metformin plus glyburide combination as therapy in failure to monotherapy in type 2 diabetic patients: one month follow-up.
    Medina Santillán R; Reyes-García G; Mateos-García E
    Proc West Pharmacol Soc; 2002; 45():139-40. PubMed ID: 12434559
    [No Abstract]   [Full Text] [Related]  

  • 19. Lactic acidosis. Lactic acidosis associated with metformin use in treatment of type 2 diabetes mellitus.
    DePalo VA; Mailer K; Yoburn D; Crausman RS
    Geriatrics; 2005 Nov; 60(11):36, 39-41. PubMed ID: 16287340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin's contraindications should be contraindicated.
    McCormack J; Johns K; Tildesley H
    CMAJ; 2005 Aug; 173(5):502-4. PubMed ID: 16129871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.